VolitionRx Limited has announced results from a clinical study evaluating its Nu.Q® Vet Feline assay for the detection of lymphoma in cats. According to the company, the assay demonstrated over 80% detection of feline lymphomas at 100% specificity, indicating no false positives. These results pave the way for what is expected to be the world’s first blood-based liquid biopsy test for feline cancer. The study results have already been announced, and the publication of the study in a peer-reviewed journal is expected to follow. VolitionRx plans to complete product development and make the Nu.Q® Vet Feline Test available through existing distribution networks.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN59207) on January 08, 2026, and is solely responsible for the information contained therein.